LUNG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pulmonx Corp (LUNG) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock has some supportive signals, but the setup is not clean enough for an impatient buyer: price is only slightly above a key resistance area, RSI is overbought, and there is no strong catalyst from news or proprietary signals. My direct view is to hold off for a better entry rather than buy now.
The short-term trend is constructive but stretched. MACD histogram is positive and expanding, which supports near-term upward momentum. However, RSI_6 at 81.05 signals the stock is overbought. Moving averages are converging, suggesting the trend is not yet firmly established. Price at 1.54 is above the pivot at 1.374 and near R1 at 1.508, with R2 at 1.59 acting as the next resistance. Support sits below at 1.24 and 1.158. Overall, the chart shows momentum, but the overbought reading makes the current entry unattractive for a beginner long-term buyer.
["Canaccord kept a Buy rating on the shares, even while lowering the price target to $5 from $6.", "Hedge funds are reported as buying aggressively, with buying amount up 1169.71% over the last quarter.", "MACD momentum is positive and expanding, indicating improving near-term price action.", "Options positioning is mildly bullish with low put-call ratios."]
["No news in the last week, so there is no fresh event-driven catalyst.", "RSI_6 at 81.05 indicates the stock is overbought.", "The analyst price target was cut from $6 to $5, which is still a positive rating but shows reduced expectations.", "SwingMax shows no recent signal and AI Stock Pick shows no signal today.", "No recent congress trading data and no notable politician/influencer buying or selling activity reported.", "The stock trend estimate is mixed, with only 50% chance and a negative one-month bias of -0.52%."]
No usable financial snapshot was provided because of a data error, so latest-quarter growth trends cannot be assessed directly. The only earnings-related detail available is that Q4 results were described as largely inline, with management acknowledging internal issues that affected performance last year and outlining actions to address them. That suggests stabilization efforts, but there is not enough financial data here to call it a strong fundamental buy.
Analyst sentiment remains positive but has softened slightly. Canaccord lowered its price target to $5 from $6 while keeping a Buy rating, implying the stock still has upside in the firm’s view but with more restrained expectations. This is constructive for Wall Street bulls, but the lowered target is a con versus a stronger growth name. Overall Wall Street view is still Buy-leaning, though not emphatically bullish.
